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Abstract:
Background: Laboratory help is must for the
diagnosis of human brucellosis due to protean
clinical manifestations. As culture is hazardous,
time consuming and less sensitive, serological
tests are preferred for the diagnosis. Aggluti-
nation tests like Rose Bengal Plate
Test (RBPT), Serum Agglutination tests (SAT),
2-Mercaptoethanol test (2-ME) that are com-
monly employed for the diagnosis either lack
sensitivity or specificity. Coombs test and
Brucellacapt though are sensitive and specific,
workout costly. Therefore, modified
coagglutination test was developed and its di-
agnostic efficacy was evaluated. Aims and Ob-
jectives: To develop modified coagglutination
test for the diagnosis of human brucellosis and
compare it with Coombs test. Materials and
Methods: Serum samples collected from 191
brucellosis patients and 100 controls were sub-
jected to RBPT, SAT, 2-ME, Coombs test and
modified coagglutination test (MCOAG). Blood
culture was performed by Castanedas method
in all the patients. Results: Significant differ-
ence in the positivity rate was seen between
MCOAG and 2-ME. The results of MCOAG
were comparable with Coombs test. Conclu-
sions: Modified coagglutination test is a bet-
ter option to Coombs test for the serodiagno-
sis of brucellosis in resource constrained coun-
tries as it is sensitive, specific & cost effective.
Key words: Brucellosis, RBPT, SAT, 2-ME,
Modified Coagglutination Test, Coombs Test.
Introduction
Brucellosis is primarily a disease of domesti-
cated animals such as cattle, goat and sheep.
Human infection can occur through exposure
to infected animals; consumption of contami-
nated, unpasteurized animal products; direct
contact with infected animal parts and inhala-
tion of infected aerosolized particles [1, 2]. In
humans it presents with non-specific symptoms
that resemble enteric fever /malaria / tubercu-
losis / rheumatoid arthritis, hence laboratory
help is necessary for the diagnosis [3-5]. Isola-
tion of Brucella organisms from the clinical
specimens is the Gold standard for diagno-
sis. However it is not routinely performed since
it is difficult, hazardous, time-consuming, lacks
sensitivity in treated patients and requires
highly skilled personnel and special level III bio
safety cabinets [3, 6].
The development of a specific PCR has over-
come some problems with culture. PCR is sen-
sitive, rapid, provides results in less than 24
hours and reduces the hazards of handling the
organism in the laboratory [7, 8]. In spite of all
these advantages, PCR is yet out of reach of
common laboratories in developing countries.
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In addition, its specificity in the clinical prac-
tice especially among high-risk group subjects
and in treated cases wherein the DNA load per-
sists for years after clinical cure remains un-
certain [9]. Hence serological tests still remain
the mainstay in diagnosis of brucellosis. Cur-
rently though an array of serological tests is
available for the diagnosis of human brucello-
sis, agglutination tests are most commonly
used. Among the agglutination tests Coombs
test and Brucellacapt are reported to be more
sensitive as well as specific [3, 10, 11,12]. Both
these tests are expensive and are out of reach
for smaller laboratories in India.
Coagglutination test has been found useful for
detection of incomplete antibodies in brucel-
losis by Ansorg [13]. Keeping this in mind,
modification of coagglutination test was devel-
oped and its efficacy was compared with
Coombs test.
Material and Methods:
Serum samples were collected from individu-
als of the following groups.
Group I: Fifty healthy high-risk group subjects
who had regular contact with animals (25 prac-
ticing veterinarians and 25 farmers).
Group II: Fifty patients, suffering from diseases
manifesting fever, other than brucellosis. These
patients were laboratory confirmed cases of
Enteric fever (N= 23), Malaria (N= 21), Den-
gue fever (N=03), Tuberculosis (N=03).
Group III: Included 191 patients with clinical
symptoms and epidemiological history com-
patible to brucellosis and antibody titers >160
IU by the Serum Agglutination Test (SAT).
The study was approved by Institutional Ethical
Committee and written informed consent was
taken from all the subjects.
All the serum samples were subjected to RBPT,
SAT, 2-ME, MCOAG and Coombs test.
The antigens for RBPT and SAT were procured
from The Division of Biological Products, In-
dian Veterinary Research Institute (I.V.R.I.);
Izatnagar, Uttar Pradesh, India. The procedures
were carried out according to the
manufacturers guidelines. For 2-ME test, 0.1
M 2-Mercaptoethanol was used in place of phe-
nol saline and further procedure was carried out
as in SAT.
The MCOAG test was performed according to
the procedure given by Ansorg et al. [13] with
some modifications. In this test serum was
treated with 2-ME instead of MnCl2 before
testing. Stable Staphylococcus aureus Cowans
I serotype (ATCC 12598) reagent (5% v/v) in
PBS with 0.01% thiomersal was prepared and
stored as stock suspension at 40C until use.
First 2-ME test was performed by standard pro-
tocol and the tubes were incubated at 37oC for
2 hours. After incubation the tubes were cen-
trifuged at 2000 rpm for 10 min. The superna-
tant was discarded and the pellet was washed
twice in normal saline. The pellet was re-sus-
pended in 0.5 ml of normal saline and 0.5 ml
Staphylococcal working reagent was added. The
working reagent was prepared by diluting the
stock to get 0.01% cell suspension. The tubes
were then incubated overnight at 37oC and re-
sults were recorded as in SAT.
The procedure for Coombs test was similar to
MCOAG test, the only difference was 0.5 ml
of antihuman globulin was used in place of Sta-
phylococcal working reagent.
Statistical Analysis:
Statistical analysis of the data was done using
Grap Pad InStat software.
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Results:
In group I, of the 50 subjects 4 showed
positive reaction by RBPT and also significant
SAT titers (>160 IU). In group II, two patients,
one with enteric fever (culture proven) and one
with malaria (positive peripheral smear for
M. falciparum) were positive by RBPT. Their
SAT titres were 80 IU and 40 IU respectively.
None of group I and group II sera showed
significant (>80 IU) titres by 2-ME, MCOAG
or Coombs tests.
In group III, of the 191 cases with SAT titers
> 160 IU, significant 2-ME titers were seen in
145. Coombs test and Modified coagglutination
test showed positive results in 151 patients.
Six patients who had insignificant 2-ME titers,
initially labelled as inactive brucellosis cases
were picked up by MCOAG and Coombs test
(which detect both complete and incomplete
antibodies) wherein the titers showed
significant rise. If only 2-ME titers were
considered these cases would not have been
treated for brucellosis. Results of various
serological tests performed are given in
(Table 1).
There was almost total correlation between
MCOAG and Coombs test titers, same titers
were obtained in 149 out of 191 sera with sig-
nificant SAT titers. In 4 cases rise in titer by
MCOAG was one dilution greater than Coombs
Table 2. SAT, 2-ME, Coombs and MCOAG Titres of 195 Suspected Cases of Brucellosis
Tests
Nil
0
46
15
13
SAT
2-ME
Coombs
MCOAG
SAT: Serum Agglutination Test, 2-ME: 2-Mercaptoethanol, MCOAG: Modified Co-Agglutination test
Titre IU/ml
20
0
0
0
2
40
0
4
29
29
80
0
25
5
5
160
45
44
52
49
320
71
43
52
54
640
34
18
25
26
1280
31
11
12
12
2560
7
4
5
5
5120
7
0
0
0
Table 1-Antibrucellar Antibodies in Different Groups by RBPT, SAT, 2-ME Coombs and
               MCOAG Tests
Groups
Screened
(Number)
Positive (Number) Significant Titers (IU)
RBPT SAT 2-ME Coombs MCOAG
04
03
191
198
04
00
191
195
00
00
145
145
00
00
151
151
00
00
151
151
50
50
191
291
Group-I
Group-II
Group-III
Total
Significant titres for SAT: > 160 IU, 2-ME/Coombs /MCOAG: > 80 IU
SAT: Serum Agglutination Test, 2-ME: 2-Mercaptoethanol, MCOAG: Modified Co-Agglutination test
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test and in 1 it was two dilutions greater. The
agglutination and clarity of supernatant was bet-
ter with MCOAG than Coombs test.
None of the control samples showed any titers
by MCOAG test thus giving the specificity of
100%. Sensitivity and specificity of MCOAG
was better than 2-ME test and was equivalent
to Coombs test.
Blood culture was performed in all the patients.
Brucella spp. could be isolated from 46 with
the isolation rate of 24.08%.
Fever, joint pain, low backache, headache, pain
abdomen, nausea, night sweats, fatigue were the
noticeable symptoms.
In this study 4 control group subjects and 46
patients showed significant SAT titres but had
insignificant 2-ME titers. Of the 46 patients, 8
had 2-ME titers of 20 IU and remaining 38 had
< 20 IU. Repeat serology after 2 and 4 weeks
in these cases did not show any rise by SAT or
2-ME tests hence these cases were considered
as cases of inactive brucellosis.
Discussion:
Brucellosis is endemic in India. Due to protean
clinical manifestations, diagnosis requires high
suspicion and laboratory aid [3-5]. Agglutina-
tion tests like RBPT and SAT have a significant
role. RBPT is used as a screening test and the
results are confirmed by SAT. But some stud-
ies suggest that significant SAT titers may be
noted in individuals with repeated subclinical
exposures as in high-risk occupations and also
in treated cases [14, 15]. In this study we have
come across 4 control individuals and 46 pa-
Test
Table 3-Comparison of Sensitivity & Specificity
              of 2-ME Test & MCOAG Test in with
              Coombs Test
2-ME
MCOAG
Compared
with
Sensitivity
(%)
Specificity
(%)
Coombs test 96
100
100
100
2-ME: 2-Mercaptoethanol, MCOAG: Modified
Co-Agglutination test
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tients with high SAT titers and insignificant 2-
ME titers. According to Young EJ, Buchanan
and Faber the diagnosis of brucellosis should
rely upon results of 2-ME tests that detect IgG
antibodies. [16, 17] However this test also suf-
fers from the disadvantage of giving false nega-
tive results due to blocking antibodies. The
blocking antibodies can be detected by Coombs
test and Brucellacapt [11, 12]. However these
tests workout costly and hence are not per-
formed in small laboratories. Hence an attempt
has been made to use modified coagglutination
test to detect non agglutinating blocking anti-
bodies in human brucellosis and compare its
efficacy with 2-ME test and Coombs tests.
When compared with 2-ME test titers, modi-
fied coagglutination has shown rise in titre in
40 patients, among which 6 have had insignifi-
cant 2-ME test titres. All of them showed
MCOAG and Coombs test titers >320 IU & hence
have been considered as cases of active bru-
cellosis and have been advised to take treatment.
Sensitivity of culture was too low probably due
to prior antibiotic treatment. All the patients
had been already treated by local doctors. None
of them was earlier diagnosed as a case of bru-
cellosis.
When compared to Coombs test, Modified
Coagglutination test is cost effective, reagents
are stable hence this test can be used in
place of Coombs test for the detection of
incomplete antibodies in human brucellosis.
Further studies are needed to substantiate these
results.
Conclusions:
In light of this study, we conclude that, positive
RBPT and significant SAT titres are not indica-
tive of an active brucellosis as these can be
positive in healthy occupationally exposed in-
dividuals. High 2-ME titres could be consid-
ered diagnostic for therapeutic purpose. Due
to false negative 2-ME test some patients with
long standing brucellosis may be missed who
can be detected by Coombs / MCOAG tests.
Coombs test can be replaced by MCOAG in
resource constrained countries as it is cost-
effective and equally specific.
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